巴曲酶治疗急性脑梗死的临床研究  

Clinical Investigation of Defirbin Therapy in Acute Cerebral Infarction

作　　者：黎祥喷[1] 杨炼红[1] 邢诒刚[1] 李梅[1] 

机构地区：[1]中山医科大学孙逸仙纪念医院神经科,510120

出　　处：《岭南急诊医学杂志》2001年第3期176-178,共3页Lingnan Journal of Emergency Medicine

摘　　要：目的:研究巴曲酶治疗急性脑梗死的临床疗效、安全性,及其对血液流变学、凝血功能的影响。方法:按照单盲、随机、对照的研究方法,将68例急性脑梗塞患者随机分为治疗组33例,对照组35例。其中对照组采用常规治疗方法,治疗组在常规治疗方法的基础上加用巴曲酶治疗。观察疗效及安全性。结果:治疗组总有效率为84.85％,与对照组总有效率60％比较,差异有显著性(P<0.05)。治疗组治疗后血浆纤维蛋白原、全血粘度、血浆粘度、血小板粘附率的变化与对照组比较,差异有显著性(P<0.05)。无明显副作用。结论:急性脑梗塞使用巴曲酶治疗能提高好转率,降低患者血粘度和血纤维蛋白原浓度,安全性高。Objective: To investigate the clinical efficacy and safety of Defirbin therapy in acute cerebral infarction, and to assess the efficacy of hemorheology and blood coagulation functional. Methods: In a single blind, random and contrasted study, 68 patients with diagnosed acute cerebral infarction were random divided into two groups, which one was treated with Defirbin and classical therapy, the other with classical therapy only. Investigate the efficacy and safety of each group. Results: The total effective rate in Defirbin group is 84.85% and contrast group is 60%, therefore Defirbin therapy was more effective than classical therapy in acute cerebral infarction( P<0.05). The changes of plasma fibrinogen, blood viscosity, plasm blood viscosity and platelet aggregation, which caused by Defirbin therapy, were more obvious than by classical therapy( P < 0.05) . Not any serious side effect in both groups was detected. Conclusion: Treating with Defirbin could rise the effective rate and decrease the blood viscosity, plasma fibrinogen concentration in acute cerebral infarction. The safety was high also.

关 键 词：急性脑梗塞 巴曲酶 治疗 

分 类 号：R743.33[医药卫生—神经病学与精神病学]